UAbstract :
UBackground:
Although recombinant interferon-alpha (rIFNα) effectively treats early myelofibrosis (eMF) patients (pts), the effect of driver and high molecular risk (HMR) mutations (muts) has not been considered. In this Phase II study, we correlate for the first time response to rIFNα treatment with driver and HMR muts.
UMethods:
Pts were diagnosed using WHO or IWG-MRT criteria. Only pts with low or intermediate 1 DIPSS score with ≥15% hematopoietic marrow foci were included. History, symptom assessment, physical exam, blood and marrow studies were performed. Genomic DNA was extracted from frozen cells; next generation targeted sequencing of 45 genes was performed. Either rIFNα-2b, 0.5 mu TIW or PEG-rIFNα-2a, 45 mcg weekly with escalation was initiated. All pts were followed at our institution; regular marrow biopsies were encouraged. IWG-MRT and ELN treatment response criteria was used.
UResults:
Of 30 pts (16 women, 14 men; median 58 yrs), 22 were low risk and 8 intermediate 1.
Two pts achieved complete remission, 9 partial, 4 clinical improvement, 7 stable disease; 3 progressed, 1 relapsed and 4 died. There were 22 JAK mutated pts, 6 CALR, and 2 MPL. 73% of pts improved or remained stable with acceptable toxicity, including 37% achieving CR or PR. There was no correlation between treatment response and baseline driver muts or DIPSS. Of 8 poor responders, 3 had ASXL1 or SRSF2. P a g e | 4
UConclusion:
Early treatment with rIFNα of pts without HMR may prevent developing marked splenomegaly, anemia, and florid myelofibrosis. Molecular profile at diagnosis may predict prognosis and treatment response.
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The successful treatment of early MF (eMF) with rIFNα has been reported by us and others, but in these studies, the effect of driver (i.e. JAK2, CALR and MPL) and epigenetic or other muts at diagnosis were not considered and systemic marrow examinations were not performed.P 1-4 P The molecular abnormalities of pts with myelofibrosis have recently been emphasized, and their incorporation into a new prognostic scoring system has been recommended as an improvement over the DIPSS (Dynamic International Prognostic Scoring System) or its variations.P 5,6 P We now report 30 pts, expanded from our initial cohort of 17, whose molecular abnormalities at baseline were correlated with hematologic and marrow response and survival following rIFNα treatment.
Molecular abnormalities at diagnosis have been investigated in pts with both primary (PMF) and secondary myelofibrosis (sMF).P 5,6,7-11 P No correlation between initial P a g e | 5 mutation status and response to treatment with ruxolitinib or overall survival was reported in pts with PMF or sMF.P 7,8 P Patel et. al. showed that pts with three or more muts had a lower overall survival and a shorter time to treatment discontinuation.P 7 P Furthermore, while individual driver muts, had no correlation with response to treatment with ruxolitinib, spleen response (≥50% reduction in palpable splenomegaly) was inversely correlated with the number of muts derived from a standard myeloid panel.
Furthermore, patients with one or more muts in ASXL1, EZH2, and IDH1/2 were significantly less likely to have a spleen response than those with none.P 7 P Recently, a number of muts have been identified categorizing pts as "high molecular risk" (HMR).P 5 P Specifically, these muts include ASXL1, EZH2, SRSF2, and IDH1/2 which have been associated with both shorter overall survival and increased risk of transformation to acute leukemia.P 5 P Further, two or more muts were associated with a worse prognosis than one or none.P 9 P Although these secondary epigenetic abnormalities have been generally accepted as associated with an adverse prognosis, their association with response to treatment with rIFNα has never been examined.
Patients with PMF and CALR muts reportedly have a better overall survival than those with JAK2, MPL, or no driver muts, whereas triple negative pts have a significantly shorter survival.P 6,10 P In multivariate analysis including both driver and epigenetic abnormalities, only CALR and ASXL1 muts remained prognostically significant; CALR had a favorable impact on prognosis, and ASXL1 a negative one.P 9 P It was therefore proposed that CALR(-) ASXL1(+) and triple negative PMF be considered HMR. These pts, however, were not treated uniformly.
P a g e | 6
We now report our results of our single-center study of 30 pts with either primary or secondary MF correlating the initial molecular and epigenetic profile with clinical and hematologic response to rIFNα.
Material and Methods:
The study was approved by our Institutional Review Board; it was performed according to the Declaration of Helsinki. Pts were diagnosed using World Health Marrow specimens were stained with hematoxylin-eosin, Giemsa, and with silver and trichrome for reticulin, and collagen. Fibrosis was graded using the European likely to be non-somatic with minor allele frequency greater than 0.25% were excluded from subsequent analysis with the exception of variants identified at least twice in the P a g e | 8
Catalog of Somatic Mutations in Cancer (COSMIC) v68.P 24
PT he cutoff point for mutation positive status for all muts was 5%.
Descriptive statistics (including mean, standard deviation, median, range, frequency, and percent) were calculated to characterize the study cohort. The 
Results:
Of 96 pts meeting the 2008 WHO criteria for PMF or IWG-MRT criteria for SMF, 66 were excluded owing to marked marrow fibrosis and < 15% hematopoietic foci or unwillingness to be treated with interferon in the early phase of their disease.P 11,12 P The remaining 30 pts (31%), met our study inclusion criteria. There were 16 women and 14 men, whose median age at the time of diagnosis was 58 years (range, 34-72 years) (Table I) died. Of the non-responders, 2 pts had a HMR, one of which had 3 muts. On the other hand, of the 12 pts with significant or moderate baseline splenomegaly, including 2 with a HMR and 3 muts and 1 pt with 4 muts 3 achieved CI, 3 remained stable, 3 progressed, and 3 died. In summary, a large spleen prior to the start of therapy was associated with worse progression-free survival and poorer response to rIFNα therapy (p=0.05, log-rank test), however, pts with a small spleen and HMR did not respond to rIFNα.
Toxicity was generally mild, grade 1 or 2, dose-related, and subsided or diminished upon dose reduction (Table IV) . These included mild depression, dryP Pskin, cough, myalgia, fatigue and asthenia. Overall, the myelosuppressive effects of rIFNα were mild. Seventeen pts developed increasing anemia (13: grade 1; 4: grade 2); one had grade 3 thrombocytopenia. In these cases, doses of interferon were temporarilyP Preduced or interrupted until cytopenias resolved. One pt developed hyperthyroidism and treatment wasP Pdiscontinued.
Follow-up BMBs were possible in 25 of 30 pts (83%). Reduction in cellularity occurred in 12, an increase in 3, and no change in 8 (baseline cellularity unreported for 2). Five pts had a reduction in reticulin fibrosis, 10 remained stable, and 9 pts had an increase (baseline fibrosis score was unreported for one). Unequivocal improvement in marrow morphology occurred in 12 of 30 (40%). However, even in the 2 patients categorized as CR according to ELN criteria, subtle abnormalities in megakaryocyte nuclear structure persisted. Of 11 pts who had reduction in splenomegaly and also evaluableP PBMBs, 8 had reduction in cellularity (73%), 2 showed no change, and one increased in cellularity. In general, therefore, the majority of pts with a reduction in spleen size had an improvement in marrow morphology.
Of the 30 pts, baseline marrow cytogenetic analyses were available in 22, and sequential cytogenetic analyses in 15. Of 13 pts with normal cytogenetics at baseline, one developed -13q, one trisomy 9 and the rest remained normal. Two pts had baseline cytogenetic abnormalities that did not change over the course of treatment: one had trisomy 9, and one -13q. These cytogenetic abnormalities have been reported previously to be favorable in this disease.P [25] [26] [27] No statistically significant differences occurred between the type of driver mut and response to treatment (IWG-MRT) (Fisher exact test, p-value = 0.65). Of the 30 pts,
There was no significant correlation between driver mut and DIPSS score at baseline (data not shown).
The mean JAK2 mutant allele burden at baseline for the low and intermediate-1
risk groups were 47.6% (range: 2-93 %) and 48.1% (10.1-95.3%), respectively. The range of baseline mutant allele burden was also similar in both groups. Of 18 follow-up specimens, 5 showed both a median mutant allele burden decrease of 23% (range, 9-58%) and a decrease in marrow cellularity after a median treatment duration of 7 yrs (range: 1.5 -12 yrs). There was no consistent or statistical correlation between decrease in JAK2P V617F P allele burden, clinical response, marrow fibrosis, or spleen size (data not shown).
Additional mut analysis was possible in 25 of 30 pts (83%) ( Table III) . Of 12 pts with CI or better, none had a known HMR mut. Of 6 pts who remained stable, 1 had a HMR mut (ASXL1). Of 8 pts who progressed or died, 7 were tested by the NGS panel and 3 had HMR (ASXL1 and SRSF2). Pts with known HMR had worse responses than those without; of 4 pts with such muts, 1 progressed and 2 died. The other remained stable. All 4 of these pts had PM. Pts with 3 or more muts did worse than those with fewer. Of 5 pts with 3 or more muts, 2 progressed and 2 died; all 4 had PMF. The other, who had post-PV MF, had PR. In addition, pts without the ASXL1mut seemed to do better than pts with it, although sample size precludes a definitive statement (p=0. 19) .
In this selected group of pts, OS and PFS at 5 years were 91.5% and 88%, respectively (Figure 1 ).
Discussion:
This is the first study correlating initial driver and epigenetic muts with documented clinical and marrow responses to rIFNα therapy. Our results suggest that therapeutic intervention with rIFNα prior to the development of clinically significant adverse features such as marked splenomegaly, anemia, and florid myelofibrosis and osteosclerosis is beneficial in pts with early stage disease. The majority of these pts improved or remained stable (73%), regardless of whether the initial DIPSS score was low or intermediate 1, suggesting that treatment with low-dose rIFNα should be initiated prior to the development of the cascading events preceding features of irreversible disease. In this selected group of pts, OS and PFS were impressive but of course, inconclusive.
Initial driver muts did not correlate with response to treatment, consistent with the response of ruxolitinib-treated MF pts; no correlation between type of genetic mut and spleen response or survival was noted in such pts, however there was an inverse correlation between number of initial muts and response. This study neither included a full myeloid mut evaluation nor treatment specification. This is important because the lack of correlation between mutational status and response to treatment may be therapy-specific and not a generality, possibly accounting for the varying results to date correlating driver and epigenetic muts and clinical results in MF. It is of interest, however, that our longest surviving patient, in CR more than 25 yrs, has a molecular profile including CALR(+) and TET2(+).
Thus, although baseline driver mut status was not useful prognostically, a molecular profile at diagnosis should be performed to identify HMR abnormalities since these negatively affected response to treatment, including rIFNα. Three of 4 pts with HMR abnormalities (ASXL1 or SRSF2) had a poor response, all with PM, compared with only 4 poor responders in 20 LMR pts.
The use of low-dose rIFNα in "early" PM, post-ET MF and post-PV MF, as defined, resulted in marrow reversion, regression of splenomegaly, and disease stabilization, with tolerable toxicity in 73% of pts. Reduction in splenomegaly appears predictive of improvement in marrow morphology and may be used as a guide for continuing therapy in the absence of HMR. We emphasize that long-term treatment must be anticipated when using low-dose rIFNα. Median duration of therapy was 5.6
years and is still ongoing for approximately 50% of the pts. That subtle but definite structural megakaryocytic abnormalities persist in pts who are considered CR suggests that "biologic remission" but not "cure" has been achieved, analogous to the responses in CML and PV.P 28 P It is therefore perhaps more appropriate to call this a complete response, as opposed to remission. Although it has been argued that "observation only" is most appropriate for lowrisk pts because of their long survival, such a recommendation does not account for interval symptoms and morbidity during the course of the disease.P 30 P We acknowledge that in following our treatment recommendations, a measurable cohort of pts may receive rIFNα prematurely. On the other hand, a significant number of pts who will require the drug may not. Unhappily, this is true for many other forms of chemotherapy.
The symptom burden in pts with MF has long been emphasized and must be considered for all pts. Patients experienced multiple toxicities.
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